Targeting a key protein to overcome drug resistance in melanoma
A Convergent Node in Melanoma to Block Multiple Oncogenic Pathways Simultaneously
['FUNDING_R01'] · UNIVERSITY OF TX MD ANDERSON CAN CTR · NIH-10861936
This study is looking at a protein called S6K1 to see how it affects melanoma and why some treatments don’t work as well for patients; by understanding this better, the researchers hope to find new ways to improve treatment for people with melanoma.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TX MD ANDERSON CAN CTR (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10861936 on ClinicalTrials.gov |
What this research studies
This research investigates the role of a protein called S6K1 in melanoma, particularly how it contributes to drug resistance in patients undergoing treatment. By analyzing patient samples and using cancer models, the study aims to understand how inhibiting S6K1 can potentially improve treatment outcomes for melanoma patients. The researchers will explore the mechanisms behind S6K1's function and its interactions with other pathways that drive melanoma progression and resistance to therapies. The ultimate goal is to develop new drugs that target S6K1 and enhance the effectiveness of existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who have experienced resistance to existing treatments or are in the early stages of the disease.
Not a fit: Patients with melanoma who are not experiencing treatment resistance or those with advanced disease that is not amenable to new therapeutic strategies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma patients, particularly those who have developed resistance to current therapies.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in melanoma, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TX MD ANDERSON CAN CTR — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KWONG, LAWRENCE — UNIVERSITY OF TX MD ANDERSON CAN CTR
- Study coordinator: KWONG, LAWRENCE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Model, CancerModel